ATA188-MS-101: An Open-Label Phase 1 Study to Evaluate the Safety of ATA188 in Subjects with Progressive and Relapsing-Remitting Multiple Sclerosis

Grants and Contracts Details

StatusActive
Effective start/end date8/20/2111/30/22

Funding

  • Atara Biotherapeutics Incorporated: $9,000.00